2 completed, 2 terminated. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 2, Terminated 2 |
Follow Apixaban 2.5 MG: new trials by email Literature Review of Apixaban 2.5 MG trials Research Report on Apixaban 2.5 MG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis Apixaban 2.5 MG, Placebo - Covid19 | Phase 3 | Completed | Thomas L. Ortel | 1291 | 2021-02-15 | 2025-02-25 |
| COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Apixaban 2.5 MG, Apixaban 5MG, Aspirin - COVID-19 | Phase 3 | Terminated | Frank C Sciurba | 657 | 2020-09-07 | 2022-02-17 |
| PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban Apixaban 5 MG, Apixaban 2.5 MG, Warfarin - Aortic Valve Disease, Aortic Valve Stenosis | Phase 3 | Terminated | Artivion Inc. | 863 | 2020-05-01 | 2024-03-20 |
| API-CAT STUDY for APIxaban Cancer Associated Thrombosis Apixaban 5 MG - Cancer-associated Thrombosis | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 1766 | 2018-10-11 | 2025-02-06 |
COVID-19 (2) · Aortic Valve Disease (1) · Aortic Valve Stenosis (1) · Neoplasms (1) · Thrombosis (1)
Artivion Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Frank C Sciurba (1) · Thomas L. Ortel (1)
United States (3) · Austria (1) · Belgium (1) · Canada (1) · France (1) · Greece (1) · Italy (1) · Netherlands (1) · Poland (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Frank Sciurba (1) · Guy Meyer, Pr (1) · John Alexander, MD (1) · Lars Svensson, MD, PhD (1) · Tracy Wang, MD (1)
PMID 37591523, PMID 34473343, PMID 34633405, PMID 36940444, PMID 37189091, PMID 37489818, PMID 38320162, PMID 40162636, PMID 41365312, PMID 42361291